Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation

Conditions

Allogeneic Hematopoietic Stem Cell Transplantation

Keywords

Immune recovery, Immunomodulatory cells, GVHD, GVL

Brief summary

The study concerns donors and patients receiving allogeneic stem cell haematopoietic transplantation. The aim of the study is to analyse HSC graft content in immune effector T (naive, memory, activated, exhausted) and immunoregulatory cell subtypes (Tregs, iNKT, MDSC) and correlate the results with post-transplant immune reconstitution of those different cell subtypes and clinical events (graft-versus-host-disease, relapse, infections). An ancillary study will focus on the impact of microbiota dysbiosis on post-transplant immune response and regulatory cell subsets.

Anne Béatrice Notarantonio, Stéphane Morisset, Romain Piucco, Michaël Pérès, Laura Boulangé et al. (21 authors)

American Journal of Hematology2025-02-044 citations

10.1002/ajh.27619

Highly immunosuppressive myeloid cells correlate with early relapse after allogeneic stem cell transplantation.

Notarantonio AB, Bertrand A, Piucco R, Fievet G, Sartelet H, Boulangé L, de Isla N, De Carvalho Bittencourt M, Hergalant S, Rubio MT, D'Aveni M.

2024-05-115 citations

10.1186/s40164-024-00516-4

Senescence and Mitochondrial Transfer Ability of Bone Marrow Mesenchymal Stromal Cells Influence Patterns of Alloreactivity after Allogeneic Hematopoietic Stem Cell Transplantation

Romain Perouf, Meriem Hadid, Alexandra Guelton, Naceur Charif, Cécile Pochon et al. (9 authors)

Blood2023-11-021 citations

10.1182/blood-2023-189093

Interventions

BIOLOGICALBlood Sample

Additional blood sample before graft, D0, D7, D15, D21, D30, D60, D90, D180, Y1, Y2

BIOLOGICALBone marrow aspiration

Additional bone marrow aspiration before graft, D30, D90, Y1

BIOLOGICALBlood sample

Before donation

BIOLOGICALAllogeneic hematopoietic stem cell sample

Allogeneic hematopoietic stem cell sample

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* patient of the Nancy CHRU, for whom a CSH allograft is planned. or * hematopoietic stem cell donors received at Nancy's CHRU for the duration of the research

Exclusion criteria

* Positive HIV * active hepatitis B or C infection

Design outcomes

Primary

Measure	Time frame
Proportions of regulatory immune cells in peripheral blood.	After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years

Secondary

Measure	Time frame
Occurrence of graft versus host (GVH) reaction after allografting of CSH	After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years
Incidence of relapse	After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years
Incidence of infections	After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years
Progress-free survival	After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years
Overall survival	After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years

Countries

France

Contacts

Primary ContactMarie-Thérèse RUBIO, PU-PH

m.rubio@chru-nancy.fr0383153257

Outcome results

None listed